Among 33 heavily pretreated patients in a Phase 1 trial, micvotabart pelidotin (MICVO) produced a confirmed objective response rate of 39% and a disease control rate of 94% in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma, with a median progression-free survival of 6.7 months versus 4.2 months on patients’ most recent prior therapy. Pyxis Oncology presented the updated data at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 19, 2026, with an October 14 data cutoff. The 81% twelve-month overall survival probability, combined with a median duration of response of 9.2 months, tells a durability story that the earlier August dataset could not.
The response signal holds across subgroups that typically predict worse outcomes. Patients who had received a prior EGFR inhibitor responded at 33% confirmed ORR, while those who had not responded at 47%. More striking, the five patients who had received a novel EGFR inhibitor showed a 60% confirmed ORR, a small but pointed number given that amivantamab received FDA approval for R/M HNSCC on November 5, 2026, specifically excluding HPV-related oropharyngeal disease. MICVO’s HPV-positive and HPV-unrelated cohorts responded at 41% and 38% respectively, suggesting the drug does not depend on HPV status for activity.
The safety picture is where the data get more complicated, and where the dose-capping decision becomes the central design question. Grade 3 peripheral neuropathy appeared in 20% of patients with prior taxane exposure versus 9% without it. The company capped doses for males above 80 kg and females above 70 kg, and the difference in outcomes is sharp: patients dosed above the cap had a 67% rate of Grade 3 peripheral neuropathy and a 56% treatment-related discontinuation rate, while capped patients had zero Grade 3 neuropathy and a 20% discontinuation rate. Capped patients also showed a higher confirmed ORR (60% versus 44%), though the groups are small. On the resolution side, 83% of the six patients who developed Grade 3 neuropathy improved to Grade 1 or better.
What the data do not yet answer is whether the response rates and durability seen in 33 patients will replicate at a scale that supports registration. The dose-capping data are directionally favorable for tolerability, but the sample sizes (nine versus five patients in the cap comparison) are too small to treat as definitive. The number to watch as enrollment continues is discontinuation rate in the capped population, since that figure will determine whether the tolerability improvement is real or a small-sample artifact.
Source link: https://www.sec.gov/Archives/edgar/data/1782223/000119312526467780/pyxs-20261118.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.

